Recent trials investigating glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists (GLP-1RAs) for the treatment of NAFLD have shown promising results
Dose AI tracks your personal progress patterns and helps optimize your results through nutrition, hydration, and side effect management
Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z
Firstly, the rapid weight loss associated with Ozempic or semaglutide can spike stress hormones and shift hormone balances both changes that can trigger more hairs than normal to enter the shedding telogen phase in their growth cycle
Established risk factors include: History of pancreatitis: Patients with prior episodes face substantially higher recurrence risk and require careful consideration before initiating GLP-1 therapy Gallstone disease: Cholelithiasis and biliary sludge can precipitate pancreatitis, particularly during periods of rapid weight loss Hypertriglyceridemia: Triglyceride levels 1,000 mg/dL significantly increase pancreatitis risk, with risk beginning to rise at levels 500 mg/dL Excessive alcohol consumption: Alcohol remains one of the most common pancreatitis triggers and may interact with metabolic changes induced by GLP-1 medications Obesity and rapid weight loss: While weight reduction is therapeutic, very rapid loss may increase gallstone formation Warning signs of acute pancreatitis that patients should recognize include severe, persistent abdominal pain, typically in the upper abdomen and often radiating to the back
Semaglutide also decreases the amount of a hormone called glucagon
